Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Biotech
Braveheart charges to $382.5M IPO to fund Hengrui cardio drug
Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
James Waldron
Aug 6, 2026 8:27am
Braveheart files for IPO to support Hengrui-licensed cardio asset
Jul 15, 2026 1:40pm
Kailera’s oral GLP-1 asset hits goals in Chinese phase 3 trials
Jul 7, 2026 8:44am
BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed
May 12, 2026 1:56am
Kailera plans $528.5 million IPO to support obesity assets
Apr 13, 2026 1:10pm
Merck KGaA drops pipeline asset from SpringWorks buyout
Mar 5, 2026 4:33pm
